Corona Remedies' Rapid Growth Driven by Tailored Business Strategies

Corona Remedies' Strategic Acquisitions Drive Growth in Branded Formulations Market

In March 2026, Corona Remedies acquired Wokadine, a povidone-iodine brand from Dr. Reddy's Laboratories for ₹95 crore. At the time, the brand was not a significant growth story, having languished in Dr. Reddy's portfolio as an ageing antiseptic with minimal promotional focus. However, Corona saw an opportunity to scale the brand, leveraging its field force and distribution network to rebuild visibility and drive growth.

The povidone-iodine market is estimated to be Rs.600–650 crore, underpenetrated and ripe for growth. Corona's strategy of reworking Wokadine's trajectory, re-engaging doctors, tightening prescriptions in institutional channels, and leveraging its field force to rebuild visibility has yielded early signs of a turnaround. This approach is a pattern that Corona has repeated across its acquisitions, reviving, scaling, and accelerating growth.

Corona's playbook is built around identifying brands with strong fundamentals but lacking commercial focus. The company has acquired several brands in the past few years, including seven from Bayer India in July 2025, Myoril from Sanofi, Vitneurin and other brands from GSK, and Obimet and Thyrocab from Abbott India. These brands were either under-promoted or sat in large portfolios, limiting their growth.